P21-activated kinase-1 (PAK-1) is a serine/threonine kinase involved in multiple signaling pathways that mediate cellular functions such as cytoskeletal motility, cell proliferation, and survival. PAK-1 expression is altered in various cancers, including prostate and breast. Our recent studies showed that prostate cancer cells expressing higher levels of PAK-1 were resistant to the cytotoxic effects of the PAK-1 inhibitor, inhibitor targeting PAK-1 activation-3 (IPA-3), compared to those with lower expression. This study expanded these findings to other cancers (breast and melanoma) by testing the hypothesis that genetic and pharmacological inhibition of PAK-1 alters cell growth, migration, and invasion in prostate, breast, and skin cancer cell lines. We also tested the specificity of IPA-3 for PAK-1 and the hypothesis that gene silenc- These data demonstrate that both pharmacological and molecular inhibition of PAK-1 decreased growth in prostate, breast, and melanoma cancer cell lines, and increased the toxicity of IPA-3 and its liposomal formulation. These data also show the specificity of IPA-3 for PAK-1, are some of the first data suggesting that IPA-3 is a therapeutic treatment for breast cancer and melanoma, and demonstrate the efficacy of liposome-encapsulated IPA-3 in breast cancer cells.
| INTRODUC TI ON
P21-activated kinases (PAKs) are serine/threonine kinases that mediate multiple signal transduction pathways, including those that control cellular functions such as cytoskeletal motility, cell proliferation, and survival.
1,2 Upregulation of PAKs in tumors is suggested to increase cellular transformation, motility, and invasion in surrounding tissues leading to cancer metastasis. 3, 4 In addition, overactivation
of PAKs results in downregulation of proapoptotic pathways and promotion of cell survival. 3 While it has been reported that PAK-6, a group II PAK, is overexpressed in prostate cancer, 5, 6 recent studies from our laboratory and others have shown that PAK-1 is also overexpressed in prostate tumor tissues and in metastasized sites in the human lung. 2, 7 PAK-1 is a major downstream effector of Rac1, which mediates cytoskeletal remodeling during prostate cancer invasion. [8] [9] [10] Previous studies showed that PAK-1 mediated the growth of prostate PC-3 cell tumor xenografts in athymic nude mice as well as the transforming growth factor-β (TGFβ)-induced prostate cancer cell epithelial-mesenchymal transition (EMT). 11 These studies suggested that PAK-1 plays a major role in prostate cancer progression and is a potential target for prostate cancer therapy. PAK-1 has also been suggested to be involved in the early stages of breast cancer and may partially participate in the mechanisms mediating the transformation of mammary epithelial cells into mesenchymal malignant cells. 12 Studies have also shown that overexpressed or hyperactivated PAK-1 mediates the anchorage independence of transformed epithelial cells during the progression of breast cancer. 12, 13 PAK-1 is also essential for AKT-and Ras-induced oncogenic transformations in both prostate and breast cancer cells. 14, 15 In addition to their catalytic active site, most PAKs, including PAK-1, have critical conformations that are required for their functions. These critical conformational sites may prove useful for the design of allosteric small molecule inhibitors whose efficacy do not depend on targeting the catalytic site of PAKs, which are ATP-binding domain common to many kinases. 16 Such precision targeting may lower off-target toxicity and increase specificity. This hypothesis is supported by data derived from an allosteric small molecule inhibitor of group I PAKs called "inhibitor targeting PAK-1 activation-3"
(IPA-3). 17 We provided further support for this hypothesis by showing that IPA-3 decreased prostate tumor growth in vitro and in vivo. 11, 18 Despite the promising effect of IPA-3 on prostate tumor growth, this compound has some drawbacks that limit its pharmacological potential. The primary one of these is that IPA-3 is metabolically unstable and required daily injections for its efficacy. 11 We addressed this limitation by developing a novel liposomal formulation of IPA-3 using sterically stabilized liposomes (SSL-IPA-3) and determined that these nanoparticles decreased prostate cancer tumor growth in vivo as compared to free IPA-3, with less frequent dosing (every 3 days).
18
Our data also showed the novel finding that both free IPA-3 and that encapsulated in SSL decreased the viability of breast cancer cells.
Not surprisingly, the efficacy of both free IPA-3 and SSL-IPA-3 correlated to PAK-1 expression in that IPA-3 was more efficacious at limiting viability in cells with lower levels of PAK-1 compared to high PAK-1 expressing cells. This raised concerns whether the efficacy of IPA-3 was truly dependent on PAK-1 expression.
This study used both pharmacological and molecular approaches to investigate the hypothesis that the efficacy of free IPA-3 and SSL-IPA-3 is dependent on the expression of PAK-1 in diverse cancer cells, including prostate and breast cancer, as well as melanoma cells.
These studies showed that cancer cells with high PAK-1 expression were less responsive to the cytotoxicity of IPA-3 and SSL-IPA-3 compared to cells with low PAK-1 expression. This current study also investigated the ability of PAK-1 gene silencing to alter prostate and breast cancer cell growth and alter markers of EMT. These data demonstrate that the toxicity of IPA-3 is partially mediated by PAK-1 expression, and support the clinical potential of SSL-IPA-3 for the treatment of cancers with altered PAK-1 expression.
| MATERIAL S AND ME THODS

| Cell lines and cell culture
The human breast cancer cell lines BT-474, MCF-7, MDA-231, MDA-468, the melanoma-derived cell line, MDA-435, and the immortalized breast epithelial cell line, MCF-10A, were purchased from ATCC. MCF-10A cells were grown in F12/DMEM (50/50) medium, and the rest of the cells were all cultured in RPMI medium. All culture media were supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin antibiotics (ATCC). The human prostate cancer cell line, DU-145, was purchased from ATCC, and was also maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin. All the cells were maintained in a humidified atmosphere at 37°C in incubators with 5% CO 2 . The DU-145 cells were chosen based on our previous studies that showed the cells to be resistant to the activity of both free and encapsulated IPA-3. 
| Lentiviral transduction
The 
| Immunoblot analysis
Cell lysates from different cell lines were collected in RIPA buffer, which contained a protease inhibitor cocktail (Santa Cruz 
| Determination of cell growth
Cell growth was measured using crystal violet staining. DU-145 and MCF-7 cells were seeded in 4000 and 10 000 cells, respectively, into each well of 6-well plates in triplicate. Cells were maintained at 37°C
for 10 days and media were changed every 3 days. Cells were fixed with 4% formaldehyde for 20 minutes and then stained using 1%
(v/v) crystal violet at room temperature for 20 minutes. Excess crystal violet staining solution was then removed and the plates were washed with water and left to air dry at room temperature. Cells were then imaged using a Canon EOS Rebel T3i camera.
| Measurement of cell migration
Cells were seeded in 6-well plates at a density of 1 × 10 6 cells/well under the above conditions. Cell migration was assessed once cells reached a confluency of at least 90% (after 48 hours) using the scratch wound healing assay as previously described. 19 Briefly, a "wound gap" was created in the cell monolayer by scratching using 1-mL pipette tips. The migration ability of the different cells was moni- The gaps from the scratch were imaged, measured, and normalized to the calculated control wound closure. 
| Measurement of cell invasion
| Preparation of sterically stabilized IPA-3 liposomes
Sterically stabilized IPA-3 (SSL-IPA-3) liposomes were prepared as described in our previous study 18 using the thin lipid hydration method followed by freeze-thaw cycles and a high-pressure extrusion. 20, 21 Our previous study also described the physical characteristics, stability, and composition of these liposomes. 18 Briefly, cholesterol (5 µmol/mL), phospholipids, including DSPC (9 µmol/mL) and DSPE-PEG (1 µmol/mL) in chloroform, and IPA-3 (4 µmol/mL) in ethanol were added into a round bottom flask, the solvents were then evaporated under vacuum in a water bath at 65°C using a rotary evaporator (Buchi Labortechnik AG). The formed thin film was then hydrated and suspended in PBS to achieve a final lipid concentration of 10 µmol/mL. The formulation then underwent five liquid nitrogen freeze-thaw cycles above the phase transition temperature of the primary lipid, prior to passing five times through a Lipex extruder (Northern Lipids, Inc) at 65°C using double stacked polycarbonate membranes (80 nm, GE Osmonics). Excess unencapsulated IPA-3 and lipids were eliminated using dialysis in 10% (w/v) sucrose for at least 20 hours with three changings of the dialysis media. Liposome suspensions were stored at 4°C, protected from light, and used within 24-48 hours of preparation. Empty SSL (made without IPA-3 encapsulation) were also formulated and used as vehicle controls.
Quantification of IPA-3 was evaluated using methods previously described by us. and their respective controls. 22 Cells were seeded in 48-well tissue culture plates at 5 x 10 4 cells/ml and incubated at 37°C in a 5% CO 2 incubator for 24 hours to allow the cells to attach and grow.
Liposomes were diluted in culture media to their final concentrations and all experiments were performed in triplicate. Cells were also treated with DMSO (vehicle control for free IPA-3) and empty liposomes (vehicle control for encapsulated IPA-3). The cells were incubated for 24, 48, and 72 hours. MTT was added at each time point, at a final concentration of 0.25 mg/mL, and plates were incubated at 37°C for 2 hours. Nonreduced MTT and media were then aspirated and replaced with DMSO to dissolve the MTT formazan crystals. Plates were shaken for additional 15 minutes and absorbance was read at 590 nm using a Spectra Max M2 plate reader (BMG Lab Technologies, Inc).
| Assessment of annexin V and propidium iodide staining
Cells in which PAK-1 was inhibited were exposed to free IPA-3 and SSL-IPA-3 dosing for 48 hours. This was followed by assessment 
| Statistical analysis
All experiments were repeated at least three times (n = 3 ( Figure 1D ).
| Transduction of shRNA decreased PAK-1 expression in DU-145 and MCF-7 cells
We chose to study the effect of PAK-1 molecular inhibition on prostate and breast cancer cell growth using DU-145 and MCF-7 cells.
DU-145 cells were chosen as these cells were shown to be resist- The decrease in expression was rechecked and was maintained in cells for 6-8 months (Supplemental Figure S2 ). These data show that stable DU-145 PAK-1 KD and MCF-7 PAK-1 KD cell lines were successfully established.
| PAK-1 knockdown altered cell morphology and growth
Inhibition of PAK-1 expression correlated to changes in the morphology of DU-145 cells as compared to their controls ( Figure 3A) .
Inhibition of PAK-1 in DU-145 resulted in a more rounded cell type as opposed to the control cells ( Figure 3A) . Furthermore, these cells never reached full confluency, even after long incubations as opposed to control cells. MCF-7 cells had a less prominent morphological change ( Figure 3A) . Besides, these cells seemed to be less adherent to the bottom of the culture flasks. Changes in cell morphology correlated to decreases in cell proliferation as assessed using crystal violet staining ( Figure 3B ,C).
| PAK-1 knockdown inhibited the migration and invasion of DU-145 and MCF-7 cells
We used the scratch and Transwell ® assays to assess the role of 
| PAK-1 knockdown altered the expression of other proteins
We further assessed the effect of PAK-1 inhibition on DU-145 and MCF-7 cell growth by determining differences in the expression of E-cadherin, N-cadherin, CXCR-4, and HCAM using immunoblot analysis ( Figure 6 ). These proteins were chosen as many studies have shown their involvement in cancer proliferation and progression. [23] [24] [25] [26] Specifically 
| PAK-1 inhibition altered the toxicity of IPA-3 to DU-145 and MCF-7 cells
We studied the effect of PAK-1 inhibition on the activity of free IPA-3
and IPA-3 encapsulated in liposomes (SSL-IPA-3) in both DU-145 and MCF-7 cells using the MTT assay. As shown in Figure 7A 
| D ISCUSS I ON
PAK-1, a serine/threonine kinase, was suggested to play a major role in various cancers. 27 Studies have even suggested that PAK-1 is a tumor oncogene and a therapeutic target for the treatment of cancer. raising the concern that the toxicity of IPA-3 may not be dependent on PAK-1 expression. We tested this possibility using a dual approach of pharmacological and molecular inhibition. As expected, both approaches decreased the growth of prostate and breast cancer cells. These data support the conclusion that toxicity of IPA-3 to cancer cells is mediated in part by PAK-1, and support the hypothesis that PAK-1 acts as an oncogene in not only prostate cancer cells, 15 but extends this hypothesis to breast cancer cells and melanoma.
Data from this study also demonstrated that PAK-1 inhibition decreased the expression of E-cadherin, CXCR-4, and HCAM. E-cadherin plays a crucial role in the epithelial adherens junctions, where several proteins interact, including α-and β-catenin, to mediate the actin cytoskeleton. 28 Inhibition of E-cadherin expression is required for EMT and plays a role in cancer migration and metastasis. 29 These data align with previous reports showing that PAK-1 regulates cytoskeletal organization and cell-cell interactions. 30 These data may also explain why PAK-1 inhibition changes the morphology of DU-145 cells. CXCR-4 is a G-protein-coupled receptor that has been shown to be overexpressed in multiple cancers and is involved in cell adhesion, survival, and growth. 31 Studies have shown that suppression of CXCR-4 in vitro inhibited cell invasion. 32 Our data agree with these findings and report the novel finding that PAK-1 regulates the and are considered models for normal breast cell function.
The overexpression of PAK-1 is believed to be responsible for the phosphorylation of the estrogen receptor, creating promiscuous phosphorylated receptors resistant to tamoxifen treatment. [39] [40] [41] Our studies further support the link between ER expression and PAK-1 expression in breast cancer cells and suggest a link between the efficacy of PAK-1 inhibitors and ER status.
We previously showed that IPA-3, in both free and in liposomal forms, inhibits prostate cancer growth in vitro and in vivo. 18 However, the efficacy of IPA-3 correlated to the expression of PAK-1, with cells that express higher levels of PAK-1 demonstrating decreased susceptibility. 18 This phenomenon extended to liposome-encapsulated IPA-3 in that SSL-IPA-3 did not decrease cell viability in DU-145 cells in our previous studies at any dose. 18 This is of concern because it suggests that these liposomal formulations may not be as efficacious in the clinic in high-grade cancers that overexpress PAK-1. This also suggests the possibility that the efficacy of both IPA-3 and SSL-IPA-3 was not specific to PAK-1. Data in this study definitely show that PAK-1 KD alters the toxicity of cells to IPA-3, however, the data do not unequivocally show that IPA-3 toxicity is totally dependent on PAK-1. It is possible that IPA-3 may also inhibit other PAK's, such as PAK-2 at higher concentrations. 17, 42, 43 The loss of PAK-1 in MCF-7 cells may have also altered the kinetics of inhibition. Further studies are needed to confirm this hypothesis.
The mechanisms mediating the increased sensitivity of prostate and breast cancer cells to SSL-IPA-3 during PAK-1 inhibition are probably not drastically different than those mediating the toxicity of free IPA-3. Most likely, the decrease in PAK-1 is shifting the dose curve to the left, essentially increasing the potency of IPA-3. This hypothesis is supported by the fact that PAK-1 inhibition resulted in similar mechanisms of cell death (apoptosis) that was seen in free IPA-3, as determined using flow cytometry. Alterations in annexin V and PI staining also confirm the morphological data and data derived from MTT staining.
While our data suggest that PAK-1 is a promising potential therapeutic target for some cancers, the IC 50 value of IPA-3 (~15 µM) is not optimal for clinical translation. This is one reason that liposomal encapsulation was used for IPA-3, which is typically limited by its stability. Nevertheless, the data also suggest that more studies are needed to develop more potent PAK-1 inhibitors. Such studies are already under way in our laboratory.
In summary, our data show that the pharmacological effect of IPA-3 is mediated, in part, by PAK-1, demonstrate some of the first data suggesting that IPA-3 is a potential therapeutic treatment for breast cancer and melanoma, and demonstrate the efficacy of liposome-encapsulated IPA-3 in breast cancer cells. This is, as far as we know, the first report of a direct correlation between PAK-1 expression and efficacy of IPA-3 in breast cancer.
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